Non-cirrhotic Portal Hypertension Associated with Didanosine and Streptococcus agalactiae Infection: A Case Report

Rev Recent Clin Trials. 2016;11(2):152-5. doi: 10.2174/1574887111666160122095814.

Abstract

Background: Non-Cirrhotic Portal Hypertension (NCPH) is a rare but potentially fatal liver disorder described in patients treated with anti-retroviral therapy for Human Immunodeficiency Virus (HIV). In particular, the most important predisposing factor to its development has been identified as prolonged exposure to Didanosine (ddI). The clinical entity of NCPH is characterized by an increase in portal pressure due to pre- or intra-hepatic causes, in absence of liver cirrhosis. However, the exact pathogenesis remains poorly understood, and due to its rarity, the diagnosis is often delayed.

Objective: We herein report a case in which ddI administration, with concomitant spontaneous bacterial peritonitis by Streptococcus agalactiae, has induced NCPH in a HIV male patient.

Conclusion: NPCH should be suspected when HIV patient with an history of ddI treatment presents liver decompensation.

MeSH terms

  • Antiviral Agents / adverse effects*
  • Didanosine / adverse effects*
  • HIV Infections
  • Humans
  • Hypertension, Portal / complications*
  • Male
  • Streptococcal Infections / complications*
  • Streptococcal Infections / drug therapy
  • Streptococcus agalactiae

Substances

  • Antiviral Agents
  • Didanosine